logo
Overview
Discover
Watchlists
Portfolios
Heatmap
Sectors
Trendscore
Performers
Alerts
Options
Earnings
Screeners
Scanners
Backtests
Strategies
Comparisons
Charts
Sign in
Discover
PYXS
Pyxis Oncology, Inc.
2.85
2 x 2.24
2 x 3.63
bid
ask
-
0.16
5.32%
2 @ 05:49 AM
2.90 +0.05 (1.75%)
Ytd147.83%
1y137.50%
2.83
day range
3.19
0.97
52 week range
5.55
Open3.01Prev Close3.01Low2.83High3.19Mkt Cap180.56M
Vol773.19KAvg Vol761.51KEPS-1.30P/EN/AForward P/E-1.40
Beta1.28Short Ratio3.13Inst. Own56.55%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning08-1350-d Avg2.01200-d Avg2.321yr Est10.00

PYXS News

benzinga.com
Pyxis Oncology Commences ~$50M Offering Of 19.6M Common Shares At $2.551/Share

Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical-stage company developing next-generation therapeutics

Pyxis Oncology Announces Up to $114 Million Private Placement Financing to Advance MICVO Through Key Clinical Milestones
globenewswire.com
Pyxis Oncology Announces Up to $114 Million Private Placement Financing to Advance MICVO Through Key

Expected to extend cash runway into the second quarter of 2027, supporting additional follow-up for

12 Health Care Stocks Moving In Friday's Intraday Session
benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session

Gainers INVO Fertility (NASDAQ:IVF) shares moved upwards by 67.3% to $2.08 during Friday's regu
benzinga.com
Pyxis Oncology Q1 EPS $(0.37), Inline

Pyxis Oncology (NASDAQ:PYXS) reported quarterly losses of $(0.37) per share which met the analyst co
benzinga.com
Wedbush Initiates Coverage On Pyxis Oncology with Outperform Rating, Announces Price Target of $6

Wedbush analyst Robert Driscoll initiates coverage on Pyxis Oncology (NASDAQ:PYXS) with a Outperf

12 Health Care Stocks Moving In Wednesday's After-Market Session
benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
benzinga.com
Pyxis Oncology To Reveal New Preclinical Data Demonstrating Synergistic Anti-Tumor Activity In A HNS

Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical-stage company developing next-generation therapeutics
benzinga.com
HC Wainwright & Co. Reiterates Buy on Pyxis Oncology, Maintains $7 Price Target

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Pyxis Oncology (NASDAQ:PYXS) wi
benzinga.com
Pyxis Oncology Q4 EPS $(0.29) Beats $(0.33) Estimate, Sales $11.038M

Pyxis Oncology (NASDAQ:PYXS) reported quarterly losses of $(0.29) per share which beat the analyst c
benzinga.com
RBC Capital Maintains Outperform on Pyxis Oncology, Lowers Price Target to $5

RBC Capital analyst Leonid Timashev maintains Pyxis Oncology (NASDAQ:PYXS) with a Outperform and

Analysts Sound Alarm On Pyxis Oncology's Tiny Trial
benzinga.com
Analysts Sound Alarm On Pyxis Oncology's Tiny Trial

Pyxis Oncology released preliminary data from Phase 1 studies of MICVO for recurrent/metastatic head

Tesla To $444? Here Are 10 Top Analyst Forecasts For Friday
benzinga.com
Tesla To $444? Here Are 10 Top Analyst Forecasts For Friday
benzinga.com
HC Wainwright & Co. Maintains Buy on Pyxis Oncology, Raises Price Target to $7

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Pyxis Oncology (NASDAQ:PYXS) wit

Nasdaq Gains Over 200 Points; US Inflation Slows To 2.7%
benzinga.com
Nasdaq Gains Over 200 Points; US Inflation Slows To 2.7%

12 Health Care Stocks Moving In Thursday's Intraday Session
benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session

Dow Surges 400 Points; Accenture Earnings Top Views
benzinga.com
Dow Surges 400 Points; Accenture Earnings Top Views
benzinga.com
Pyxis Oncology Shares Early Phase 1 Data For MICVO Showing Meaningful Clinical Activity In Recurrent

46% confirmed objective response rate (ORR) and 92% disease control rate (DCR) observed with MICVO a

12 Health Care Stocks Moving In Thursday's Pre-Market Session
benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
benzinga.com
Stephens & Co. Maintains Overweight on Pyxis Oncology, Raises Price Target to $8

Stephens & Co. analyst Sudan Loganathan maintains Pyxis Oncology (NASDAQ:PYXS) with a Overwei
benzinga.com
Guggenheim Maintains Buy on Pyxis Oncology, Raises Price Target to $7

Guggenheim analyst Brad Canino maintains Pyxis Oncology (NASDAQ:PYXS) with a Buy and raises the p
benzinga.com
Pyxis Oncology Q3 EPS $(0.35) Misses $(0.34) Estimate

Pyxis Oncology (NASDAQ:PYXS) reported quarterly losses of $(0.35) per share which missed the analyst
benzinga.com
Pyxis Oncology To Present Translational Data For Micvotabart Pelidotin At Upcoming Medical Meetings;

BOSTON, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical-stage compa
benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
benzinga.com
Guggenheim Initiates Coverage On Pyxis Oncology with Buy Rating, Announces Price Target of $5

Guggenheim analyst Brad Canino initiates coverage on Pyxis Oncology (NASDAQ:PYXS) with a Buy rati
benzinga.com
HC Wainwright & Co. Reiterates Buy on Pyxis Oncology, Maintains $5 Price Target

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Pyxis Oncology (NASDAQ:PYXS) wi
benzinga.com
Pyxis Oncology Q2 EPS $(0.30) Beats $(0.35) Estimate, Sales $2.82M

Pyxis Oncology (NASDAQ:PYXS) reported quarterly losses of $(0.30) per share which beat the analyst c
benzinga.com
Pyxis Oncology Updates Enrollment for Phase 1 Trial of New Cancer Drug Micvo

On July 31, 2025, revisions to patient enrollment participants related to Pyxis Oncology, Inc.'s
benzinga.com
HC Wainwright & Co. Reiterates Buy on Pyxis Oncology, Maintains $5 Price Target

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Pyxis Oncology (NASDAQ:PYXS) wi
benzinga.com
Pyxis Oncology Announces Robust Preclinical Data Supporting Unique Extracellular Linker Payload Clea

Gene signatures associated with increased efficacy of micvotabart pelidotin (MICVO) due to greater l
benzinga.com
Pyxis Oncology Will Present New Preclinical Data Supporting Development Of First-In-Concept Antibody

Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical-stage company developing next-generation therapeutics
benzinga.com
RBC Capital Reiterates Outperform on Pyxis Oncology, Maintains $8 Price Target

RBC Capital analyst Leonid Timashev reiterates Pyxis Oncology (NASDAQ:PYXS) with a Outperform and
benzinga.com
HC Wainwright & Co. Reiterates Buy on Pyxis Oncology, Maintains $5 Price Target

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Pyxis Oncology (NASDAQ:PYXS) wi
benzinga.com
Pyxis Oncology FY 2024 GAAP EPS $(1.32) Misses $(1.09) Estimate, Sales $16.15M Beat $13.81M Estimate

Pyxis Oncology (NASDAQ:PYXS) reported quarterly losses of $(1.32) per share which missed the analyst
benzinga.com
Pyxis Oncology's Deprioritizes Second Pipeline Asset, Analyst Applauds Move

Pyxis Oncology prioritizes PYX-201 with promising Phase 1 results in solid tumors, while deprioritiz
benzinga.com
HC Wainwright & Co. Reiterates Buy on Pyxis Oncology, Lowers Price Target to $5

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Pyxis Oncology (NASDAQ:PYXS) wi
benzinga.com
RBC Capital Reiterates Outperform on Pyxis Oncology, Lowers Price Target to $8

RBC Capital analyst Leonid Timashev reiterates Pyxis Oncology (NASDAQ:PYXS) with a Outperform and
benzinga.com
Pyxis Oncology Plans Portfolio Prioritization, Focusing Resources On Advancing Its Lead Clinical Pro

Pyxis Oncology's second clinical program, PYX-106 — a fully human IgG1 monoclonal antibody targe
benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
benzinga.com
Nasdaq Edges Higher; Baidu Shares Fall After Q3 Results
benzinga.com
Crude Oil Gains 1%; Deere Posts Better-Than-Expected Earnings
benzinga.com
Dow Jumps Over 100 Points; Nvidia Posts Upbeat Earnings
benzinga.com
RBC Capital Maintains Outperform on Pyxis Oncology, Raises Price Target to $10

RBC Capital analyst Leonid Timashev maintains Pyxis Oncology (NASDAQ:PYXS) with a Outperform and

benzinga.com
Pyxis Oncology's Cancer Drug Progress Stirs Analyst Concerns

Pyxis Oncology announces mixed Phase 1 PYX-201 data, collaboration with Merck, and analyst downgrade
benzinga.com
Market-Moving News for November 21st

TRNR: 81% | Interactive Strength Board Approves Maximum Cumulative Bitcoin Purchase Of Up To $5M; Pl
benzinga.com
William Blair Downgrades Pyxis Oncology to Market Perform

William Blair analyst Andy Hsieh downgrades Pyxis Oncology (NASDAQ:PYXS) from Outperform to Marke
benzinga.com
HC Wainwright & Co. Reiterates Buy on Pyxis Oncology, Maintains $7 Price Target

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Pyxis Oncology (NASDAQ:PYXS) wi
benzinga.com
Pyxis Oncology Q3 2024 GAAP EPS $(0.35) Misses $(0.31) Estimate

Pyxis Oncology (NASDAQ:PYXS) reported quarterly losses of $(0.35) per share which missed the analyst
benzinga.com
Pyxis Oncology's Cancer Drug Platform Shows Potential, Analyst Sees Over 190% Upside

Stephens initiates coverage on Pyxis Oncology (PYXS), highlighting its promising ADC technology and

benzinga.com
Stephens & Co. Initiates Coverage On Pyxis Oncology with Overweight Rating, Announces Price Target o

Stephens & Co. analyst Sudan Loganathan initiates coverage on Pyxis Oncology (NASDAQ:PYXS) wi
benzinga.com
RBC Capital Reiterates Outperform on Pyxis Oncology, Maintains $7 Price Target

RBC Capital analyst Leonid Timashev reiterates Pyxis Oncology (NASDAQ:PYXS) with a Outperform and